A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
The Company develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. There are currently 18 Arrowhead discovered drug candidates in clinical trials ranging from early stage (Phase 1) to late stage (Phase 3). In addition, the company has a robust discovery stage pipeline which is capable of generating multiple new clinical candidates each year. The Company recently achieved a transformational milestone with its first commercial launch in 2025, when the U.S. Food and Drug Administration ("FDA") approved REDEMPLO® (plozasiran) as an adjunct to diet to reduce triglycerides in adults with Familial Chylomicronemia Syndrome ("FCS").
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 1.1B | 829M | - | 241M | 243M | 138M |
| Net Income | 202M | -1.6M | -599M | -205M | -176M | -141M |
| EPS | $1.46 | $-0.01 | $-5.00 | $-1.92 | $-1.67 | $-1.36 |
| Free Cash Flow | 322M | 157M | -604M | -331M | -189M | 148M |
| ROIC | 152.9% | 49.7% | -141.1% | -61.3% | -43.6% | -32.4% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.57 | 0.46 | 2.12 | 1.76 | 0.69 | 0.74 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | 301M | 98M | -601M | -205M | -179M | -149M |
| Operating Margin | 27.6% | 11.9% | - | -85.2% | -73.4% | -107.8% |
| ROE | 35.6% | -0.5% | -262.5% | -61.3% | -43.6% | -32.4% |
| Shares Outstanding | 137M | 163M | 120M | 107M | 105M | 104M |
ARROWHEAD PHARMACEUTICALS, INC. passes 1 of 9 quality checks, indicating weak fundamentals.
ARROWHEAD PHARMACEUTICALS, INC. trades at 39.9x trailing earnings, compared to its 15-year median P/E of 39.1x, suggesting it is currently Expensive relative to its historical range. On a free-cash-flow basis, the stock trades at 27.7x vs a median of 34.1x. At current prices, the estimated annualized return to fair value is +9.1%.
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) has a current P/E ratio of 39.9, compared to its historical median P/E of 39.1. The stock is currently considered Expensive based on its historical valuation range.
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) has a 5-year average return on invested capital (ROIC) of -45.7%. This is below average and may indicate limited pricing power.
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) has a market capitalization of $8.8B. It is classified as a mid-cap stock.
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) does not currently pay a regular dividend.
Based on historical P/E analysis, ARROWHEAD PHARMACEUTICALS, INC. (ARWR) appears expensive. The current P/E of 39.9 is 2% above its historical median of 39.1. The estimated fair value CAGR (P/E method) is 4.7%.
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) reported annual revenue of $829 million in its most recent fiscal year, based on SEC EDGAR filings.
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) has a net profit margin of -0.2%. The company is currently unprofitable.
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) generated $157 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) has a debt-to-equity ratio of 0.46. This indicates a conservatively financed balance sheet.
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) reported earnings per share (EPS) of $-0.01 in its most recent fiscal year.
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) has a return on equity (ROE) of -0.5%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 16 years of financial data for ARROWHEAD PHARMACEUTICALS, INC. (ARWR), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) has a book value per share of $2.86, based on its most recent annual SEC filing.